Could This Smaller Biotech Rival Allergan's Blockbuster Botox?

Revance Therapeutics (RVNC) launched to a nearly two-year high Tuesday on Phase 3 data for a frown line-treatment that would rival Allergan's (AGN) Botox but likely won't come on the market until 2020, if approved.

X In afternoon trading on the stock market today, Revance soared by 38.7%, near 36.10, and broke out of a flat base with a buy point at 28.85. Intraday, shares touched a high last seen in January 2016. Allergan sank 1.4%, near 164.60.

The treatment, called RT002, is used to treat...

What feeling does this article give you?

#hashtags to follow:

Revance Therapeutics [+]    RVNC [+]    Phase 3 [+]    Allergan [+]    AGN [+]    Botox [+]    January 2016 [+]   

More #news: